Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Deep Diving into the Pathogenesis of C3 Glomerulopathy, With Sayna Norouzi

 is increasingly understood not as a single disease entity but as a histopathologic pattern of kidney injury driven by dysregulation of the alternative pathway of the complement system.

Although rare, new insights into complement dysregulation are reshaping its diagnostic and therapeutic framework, according to this recently published review.

“So I think the rarity of the disease is something that affects both sides,” said Sayna Norouzi, MD, clinical nephrologist and associate professor of medicine at Loma Linda University Medical Center. “A lot of physicians might not be comfortable treating C3G because they've never seen a patient before, and they don't feel comfortable starting treatment for these patients.”

With an estimated incidence of 0.2–2 cases per million people annually, C3G remains ultrarare and diagnostically challenging. Patients commonly present with proteinuria, hematuria, and progressive kidney function decline—features that overlap with other glomerular diseases. As a result, accurate diagnosis increasingly depends on understanding the underlying complement-mediated mechanism driving injury.

The complement system can be activated through 3 pathways: classical, lectin, and alternative. The classical pathway is triggered by antigen–antibody complexes, while the lectin pathway is activated by carbohydrate patterns on microbial surfaces. The alternative pathway is distinct in its ability to activate spontaneously through continuous low-level hydrolysis of C3, a process known as “C3 tick-over,” which generates C3a and C3b fragments.

Once initiated, the alternative pathway undergoes amplification through an enzymatic loop in which C3b binds factor B and is cleaved by factor D, forming the alternative pathway C3 convertase. This complex drives further C3 cleavage, creating a powerful amplification system. Under normal physiologic conditions, regulatory proteins, including complement factor H, complement factor I, and membrane cofactor protein (CD46), control this process by inactivating C3b and limiting C3 convertase activity to prevent host tissue injury.

Both genetic and acquired abnormalities contribute to dysregulation of the alternative pathway. Genetic variants have been identified in approximately 25%–40% of patients and affect complement components such as C3 and factor B, as well as regulatory proteins including factor H, factor I, complement factor H-related protein 5, and membrane cofactor protein. Acquired drivers, including autoantibodies stabilizing C3 convertase, may further amplify complement activation.

The downstream effect is uncontrolled alternative pathway activity, excessive C3 convertase formation, and dominant C3 deposition within the glomeruli, which has been described as the defining histopathologic feature of C3G.

According to investigators, the kidney appears particularly vulnerable to this dysregulation. The glomerular basement membrane lacks membrane-bound complement regulators and relies heavily on circulating regulators such as factor H for protection.

When this regulation fails, persistent complement activation generates proinflammatory mediators, including C3a and C5a, promotes opsonization through C3b, and culminates in the formation of the terminal membrane attack complex (C5b-9), ultimately driving glomerular cell injury and progressive renal dysfunction.

As understanding of these mechanisms deepens, clinicians are increasingly able to connect histopathology with molecular drivers of disease. For Norouzi and others in the field, this evolving insight represents more than scientific progress; it may help reduce diagnostic uncertainty and increase clinician confidence in managing a condition that, while rare, carries significant morbidity.

Editor's Note: Norouzi reports relevant disclosures with Calliditas, Travere, Apellis, and others.

Mashayekhi M, Zuckerman JE, Barratt J, et al. C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies. Kidney Medicine. 2026;8(3):101258. doi:

https://doi.org/10.1016/j.xkme.2026.101258

Gashu Ayehu, Atari M, Hassanein M, Jhaveri KD. C3 Glomerulopathy. Nih.gov. Published November 5, 2024. 

https://www.ncbi.nlm.nih.gov/books/NBK609090/

Videos

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

 2026 annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)

 in Philadelphia from February 28 – March 2, Joseph Han, MD, from Old Dominion University, highlighted new data from a post hoc pooled analysis of ANCHOR-1 and ANCHOR-2 evaluating twice-yearly depemokimab in patients with 

chronic rhinosinusitis with nasal polyps (CRSwNP)

 marked by type 2 (T2) inflammation and disease recurrence following surgery.

Depemokimab, an ultra–long-acting anti–IL-5 biologic, is designed for administration every 26 weeks, offering sustained suppression of eosinophilic inflammation. The analysis focused on a clinically relevant subgroup: adults with ≥ prior nasal polyp surgery and ≥ 1 T2 inflammatory feature, including blood eosinophils ≥150 cells/μL, comorbid asthma, or NSAID- or aspirin-exacerbated respiratory disease. In real-world practice, this is the population most likely to be considered for biologic therapy.

A total of 154 patients were included in the pooled analysis (79 receiving depemokimab and 75 receiving a placebo). Across multiple endpoints, depemokimab demonstrated higher responder rates compared with placebo at 52 weeks.

“If we had to summarize what...the presentation showed was that if you use depemokimab in patients who would normally get [a] biologic in a real-world setting, that it does much better than what we saw from the results of ANCHOR-1 and ANCHOR-2,” Han told

For nasal obstruction, assessed using the verbal response scale, 46% of patients receiving depemokimab achieved ≥a 1-point reduction, compared with 21% with placebo (odds ratio [OR] 2.82; 95% CI 1.37–5.78; 

 =.006). Improvements in loss of smell (≥ 0.9-point decrease) were observed in 29% versus 15% (OR, 2.35; 

Clinically meaningful improvements in health-related quality of life, measured by SNOT-22 (≥ 8.9-point decrease), occurred in 65% of treated patients versus 43% on placebo (OR, 2.25;

 =0.019). Nasal polyp score response (≥ 1-point decrease) was achieved in 41% versus 25% (OR 2.04; 

Rescue intervention use, defined as the need for systemic corticosteroids or additional surgery, was significantly lower with depemokimab: 19% compared with 37% in the placebo arm (OR, 0.34; 95% CI 0.16–0.75; 

 =.008). According to Han, this reduction in rescue interventions reflects better control of underlying inflammation and fewer acute exacerbations requiring escalation of care.

During the interview, Han discussed the clinical implications of a twice-yearly treatment for CRSwNP. He cited market survey data evaluating patient preferences for medication delivery, including whether patients would favor a subcutaneous injection every 6 months over a daily oral pill.

“What this tells us is that… patients would prefer [depemokimab every 6 months) rather than taking a pill every day,” Han said.

Relevant disclosures include GlaxoSmithKline, LLC., Medtronic, Inc., Regeneron Healthcare Solutions, Inc., GENZYME CORPORATION, Optinose US, Inc., Medtronic, Inc., AstraZeneca

Pharmaceuticals LP, and AERIN MEDICAL INC.

Han J, Lee S, Soler Z, et al. Twice-Yearly Depemokimab Delivers Clinically Meaningful Improvements in Patients With CRSwNP With Features of T2 inflammation and Disease Recurrence Following Surgery: Post Hoc Pooled Analysis of ANCHOR-1/-2. 

Journal of Allergy and Clinical Immunology

. 2026;157(2):AB434. doi:https://doi.org/10.1016/j.jaci.2025.12.973

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

February 2026 spotlighted a wave of innovation in genetic and translational hepatology, particularly in alpha-1 antitrypsin deficiency (AATD). Interim data for YOLT-202 demonstrated that a single in vivo base-editing dose could meaningfully increase functional AAT levels, while TSRA-196 earned both Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA), reinforcing growing regulatory support for one-time gene-editing strategies aimed at correcting the underlying PiZZ mutation.

Beyond gene editing, the month reflected broader advances across metabolic, viral, and cholestatic liver disease. Preclinical data using a human Liver-on-a-Chip platform suggested disease-modifying potential for Thykamine in metabolic dysfunction-associated steatohepatitis (MASH), offering a translational bridge between animal models and human systems. At the population level, emerging data showing declining hepatitis B birth dose vaccination rates raised concerns about long-term liver cancer risk, while new research challenged persistent hesitancy around statin use in primary biliary cholangitis (PBC). Rounding out February, Rare Disease Day brought renewed attention to biliary atresia, underscoring the urgency of early recognition in altering lifelong outcomes.

Check out this February 2026 hepatology month in review for a recap of 

’s coverage of the top hepatic news and research from the past few weeks:

Single Dose YOLT-202 Gene-Editing Therapy Increases Functional AAT Levels in AATD

On February 19, 2026, YolTech Therapeutics announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational 

 base editing therapy, for the treatment of AATD. Findings demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels.

Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip Platform

On February 19, 2026, Devonian Health Group announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human MASH model using PhysioMimix® Liver-on-a-Chip platform. Findings suggest Thykamine exerts dose-dependent effects on key pathological hallmarks of MASH, including fibrosis and inflammation, in a physiologically relevant human liver system, representing a notable translational bridge between Devonian’s previously disclosed efficacy in the mouse STAM® MASH model and a predictive human microphysiological model.

TSRA-196 Gets FDA Fast Track, Orphan Drug Designations for AATD

On February 23, 2026, the FDA granted Fast Track and Orphan Drug designations to TSRA-196, an 

 gene editing program from Tessera Therapeutics, for the treatment of adults with AATD who are homozygous for the PiZ allele (PiZZ). TSRA-196 is being jointly developed with Regeneron and is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional AAT protein through a one-time, durable treatment option for patients.

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS

Emerging research suggests hepatitis B birth dose vaccination is on the decline, posing important implications for rising chronic infection and future liver cancer risk. The study found that rates of the newborn hepatitis B vaccine declined by > 10% over the past 2 years in the United States. Of note, this decline occurred before updated recommendations from the Advisory Committee on Immunization Practices (ACIP) in December 2025 and subsequent updated guidance from the Centers for Disease Control and Prevention (CDC) in January 2026.

Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD

​​For many years, concerns about hepatotoxicity have contributed to hesitancy around prescribing statins in patients with chronic liver disease. While recent research has largely addressed and dispelled these concerns, a lack of studies specific to cholestatic conditions like PBC have resulted in continued hesitancy. A recent study from Jonggi Choi, MD, PhD, and colleagues points to a reduced risk of hepatic decompensation and major liver events in patients with PBC taking statins, supporting a potential protective effect in this population.

Rare but Critical: Recognizing the Signs and Rewriting the Story Around Biliary Atresia

In honor of Rare Disease Day, celebrated on February 28 each year, the editorial team of HCPLive spoke with families and clinicians to highlight the race against time in biliary atresia, a rare hepatic condition where early recognition can change the course of a child’s life.

Recognizing the Signs and Rewriting the Story Around Biliary Atresia

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Alpha-1 antitrypsin deficiency

6 Hepatology Headlines You Missed in February 2026

Nada Elbuluk, MD, MSc, is a dermatologist in California. 

Susan Taylor, MD, a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. 

Where Are We in 2026 in Skin Health Equity Progress?

, Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale School of Medicine and host of 

, led a clinician-focused discussion with Susan Taylor, MD, the Bernett Johnson Endowed Professor of Dermatology at the University of Pennsylvania Perelman School of Medicine, and Nada Elbuluk, MD, MSc, board-certified dermatologist and Professor at the USC Keck School of Medicine, Department of Dermatology, on what “skin health equity” means in practice, and why this moment represents an inflection point for the 

Shahriari emphasized that the phrase “skin health equity” was chosen intentionally. For today’s dermatologists, she noted, the conversation must extend beyond isolated diagnoses or cosmetic concerns to encompass outcomes, access, education, and trust. What once was discussed quietly “in the hallways” is now visible in the literature, on social media, and across industry initiatives. The shift, she suggested, is from performative concern to measurable accountability: clinicians, institutions, and companies are increasingly being asked to demonstrate what they are doing differently.

Taylor reflected on why this period feels distinct from prior waves of discussion. In her view, one of the most tangible differences is therapeutic progress in diseases that have historically and disproportionately affected patients with skin of color. She pointed to hidradenitis suppurativa (HS) and atopic dermatitis as examples in which clinicians now have more effective and safer treatment options than in years past. These therapeutic advances, she explained, are complemented by educational gains, including expanded image collections and textbooks that more comprehensively depict dermatologic disease across a spectrum of skin tones. Such resources are critical for improving diagnostic accuracy and reducing delays in care.

Elbuluk agreed that the landscape has evolved from dialogue to accountability. She observed that journals, conferences, pharmaceutical companies, and even the cosmeceutical industry are now explicitly prioritizing health equity. Whereas prior limitations, such as a lack of diverse representation in research or educational materials, might have been passively accepted, there is now an expectation that organizations address these gaps. According to Elbuluk, that expectation signals a readiness within the field to pivot from aspiration to implementation.

Shahriari also framed equity as a patient safety issue. As the US population becomes increasingly diverse, she argued, the inability to effectively diagnose and manage dermatologic disease across heterogeneous skin types risks compromising care. For practicing clinicians, this reframing underscores that equity is not ancillary to core dermatologic practice; it is foundational to delivering safe, high-quality care.

The discussion also addressed ongoing gaps. Taylor highlighted clinical trials as an area of both progress and unfinished work. She cited efforts to increase the diversity of both investigators and study participants, noting initiatives supported by professional organizations and pharmaceutical companies. Trials intentionally designed to evaluate therapies in patients with skin of color represent an encouraging step, but she stressed that sustained commitment is necessary to ensure study populations reflect real-world demographics.

Beyond research, Elbuluk pointed to changes in conference programming and educational content. Speakers are becoming more intentional about including diverse imagery in lectures, and sessions addressing conditions that disproportionately affect patients of color are more visible. Importantly, she noted that skin of color dermatology is increasingly integrated throughout meetings and curricula, rather than siloed as a standalone topic, an evolution that reinforces its relevance to all clinicians.

Collectively, the panelists conveyed cautious optimism. Meaningful gains have been made in therapeutics, education, and representation, but structural and clinical gaps remain. For dermatologists in practice, the message was clear: progress matters only if accompanied by honest appraisal and continued action to ensure equitable, evidence-based care for all patients.

Editor’s note: This summary was developed with the help of AI tools.

In this segment from the latest episode of the Skin of Color Savvy podcast, progress in skin health equity and advancements still needed in 2026 are highlighted.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a comprehensive update on the rapidly evolving landscape of incretin-based therapies, focusing on newly published and top-line clinical trial data across oral GLP-1 receptor agonists and emerging triple agonists.

00:00:22 Orforglipron in the ACHIEVE-3 trial

00:10:28 Retatrutide in the TRIUMPH-4 trial

00:18:26 Topline data on Novo Nordisk's UBT251

00:21:47 Price cuts on Ozempic, Rybelsus, and Wegovy in 2027

The discussion begins with the phase 3 ACHIEVE-3 trial evaluating orforglipron, a novel, nonpeptide, once-daily oral GLP-1 receptor agonist, studied head-to-head against oral semaglutide in 1,698 adults with type 2 diabetes inadequately controlled on metformin. Orforglipron demonstrated superior glycemic efficacy, achieving mean A1C reductions of 1.7% and 1.9% at the 12 mg and 36 mg doses, respectively, compared with 1.2% and 1.5% reductions seen with 7 mg and 14 mg oral semaglutide. All primary noninferiority endpoints were met, with statistical superiority observed across comparisons. Weight reduction also favored orforglipron.

However, the enhanced efficacy was accompanied by higher rates of gastrointestinal adverse events. Nausea and other GI symptoms were reported in approximately 58–59% of patients receiving orforglipron versus 37–45% with semaglutide. Importantly, treatment discontinuation due to GI events remained relatively low (6% with orforglipron vs 3% with semaglutide), suggesting tolerability may be manageable in clinical practice. The hosts emphasize the importance of understanding how adverse events are captured in trials and highlight the role of dose titration, dietary counseling, and supportive medications in mitigating side effects. A key limitation noted is the absence of cardiovascular outcomes data for orforglipron, particularly given established cardiovascular benefit with oral semaglutide, underscoring the need for outcomes-driven decision-making in high-risk populations.

Attention then shifts to top-line results from the phase 3 TRIUMPH-4 trial evaluating retatrutide, a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, in individuals with obesity and osteoarthritis. Over 68 weeks, retatrutide achieved mean weight reductions of 26.4% to 28.7% (up to 71.2 pounds), representing some of the most substantial weight loss observed in pharmacotherapy trials to date. Nearly half of participants achieved ≥25% weight loss, and up to 23.7% achieved ≥35% reduction. Clinically meaningful improvements in osteoarthritis symptoms were documented via WOMAC scoring, with one in eight participants reporting complete resolution of knee pain. Gastrointestinal adverse events were dose-dependent, and discontinuation rates ranged from 12% to 18%, reinforcing the importance of balancing efficacy with tolerability.

The hosts also review early phase 2 data from Novo Nordisk’s investigational triple agonist (UBT251), which demonstrated 19.7% weight loss over 24 weeks in a Chinese cohort, along with improvements in waist circumference, glycemia, blood pressure, and lipids. Although preliminary, these findings highlight growing competition in the triple-agonist space and suggest continued acceleration in therapeutic innovation.

The episode concludes with broader reflections on expanding indications for incretin-based agents, including cardiovascular disease, osteoarthritis, sleep apnea, and potentially other cardiometabolic and inflammatory conditions, alongside discussion of anticipated price reductions and increased market competition. Isaacs and Bellini characterize the current era as transformative, with incretin-based therapies poised to substantially reshape cardiometabolic risk reduction strategies in type 2 diabetes and obesity.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. February 26, 2026. Accessed March 2, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. Accessed March 2, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

Novo Nordisk. Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China. 

. February 24, 2026. Accessed March 2, 2026. 

https://www.globenewswire.com/news-release/2026/02/24/3243205/0/en/Novo-Nordisk-Triple-agonist-UBT251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-China.html

Podcasts

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.

Video Series

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Wei-Xing Zong, PhD, is Distinguished Professor and Chair of the Department of Chemical Biology at Rutgers University.

Articles

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management. 

Dietary Protein as a Modifiable Risk Factor in Liver Cancer, With Wei-Xing Zong, PhD

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Berotralstat Cuts HAE Attack Burden in APeX-P Interim Analysis, With Jolanta Bernatoniene, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up with FDA decisions, key trial results, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

5 Cardiology Headlines You Missed in February 2026

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

ADVANCE OUTCOMES: Ralinepag Outperforms Placebo in Slowing Disease Progression in PAH

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera. 


Hematology

FDA News

FDA Accepts New Drug Application for Rusfertide, Grants Priority Review In Polycythemia Vera

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.

Future Advancements in PBC Care: Innovations on the Horizon

Neal Bhatia, MD, speaks on new data on ixekizumab and tirzepatide for weight loss and psoriasis, as well as the implications of these data regarding GLP-1 use.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing GLP-1 or Dual Incretin Therapies in IL-17 Mediated Disease, With Neal Bhatia, MD

Medical student at John Sealy School of Medicine, University of Texas in Galveston

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Latest News

Deep Diving into the Pathogenesis of C3 Glomerulopathy, With Sayna Norouzi

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

6 Hepatology Headlines You Missed in February 2026

Where Are We in 2026 in Skin Health Equity Progress?

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates